Launched at the end of 2017, The Pioneer Project aims to understand and overcome resistance to anti-PD-1(L1) immunotherapies in patients with advanced lung cancer. To date, 116 patients have already been included in the project and some of them have joined the clinical trial that aims to bypass these resistances with next generation immunotherapies.
As in all of our studies, patient safety is our top priority and our decisions are based on an individualized benefit-risk assessment which, for most of these patients who have failed therapy, remains very favorable. This is why we all remain committed and actively continue to recruit new patients who want to participate in the Pioneer clinical trial and in the biomarker component of the project.
The objective of the clinicians, scientists and industrials of the Pioneer collective remains the same: to ensure that patients facing deadliest cancer benefit from the best of immuno-oncology research and innovation, even in these exceptional circumstances.
Dr. Marie ROUMIEUX